| |
Primary analysis N = 73
|
Secondary analysis N = 122
|
|---|
|
Gender
| | |
|
Male
|
33 (42%)
|
62 (51%)
|
|
Female
|
39 (53%)
|
56 (46%)
|
|
Admitting team
|
|
Medical Oncology
|
47 (64%)
|
85 (70%)
|
|
Radiation Oncology
|
17 (23%)
|
22 (18%)
|
|
Palliative Care
|
7 (10%)
|
9 (7%)
|
|
Admission indication
|
|
Symptom management
|
55 (75%)
|
88 (72%)
|
|
Tumour type
|
|
Lung
|
14 (19%)
|
23 (20%)
|
|
Gastric and other upper GI
|
11 (15%)
|
15 (12%)
|
|
Breast
|
10 (14%)
|
14 (11.5%)
|
|
Prostate
|
3 (4%)
|
13 (11%)
|
|
Colon
|
8 (11%)
|
9 (7%)
|
|
Other
|
23 (31.5%)
|
39 (32%)
|
|
Tumour stage
|
|
Stage I or II
|
8 (11%)
|
10 (8%)
|
|
Stage III
|
12 (16%)
|
19 (15%)
|
|
Stage IV
|
50 (68.5%)
|
85 (69.7%)
|
|
Site of metastasis
|
|
No documented metastasis
|
20 (27%)
|
32 (26%)
|
|
Bone
|
18 (25%)
|
24 (20%)
|
|
Liver
|
10 (14%)
|
13 (11%)
|
|
Lung
|
4 (5.5%)
|
7 (6%)
|
|
Brain
|
3 (4%)
|
9 (7%)
|
|
Multiple sites
|
12 (16%)
|
25 (20.5%)
|
|
Unknown/missing
|
6 (8%)
|
10 (8%)
|
|
ECOG Score
|
|
1 or less
|
22 (30%)
|
31 (25%)
|
|
2
|
22 (30%)
|
40 (33%)
|
|
3 or more
|
19 (26%)
|
34 (28%)
|
|
Unknown/missing
|
10 (14%)
|
17 (14%)
|
|
SQiD informant cohabitation with patient
|
41 (56%)
|
69 (57%)
|
| |
Median (IQR)
|
Median (IQR)
|
|
Age
|
68 (60.5–78)
|
68 (56–77.5)
|
|
Australia-Modified Karnofsky Score
|
70 (50–80)
|
70 (50–70)
|
- GI Gastro intestinal, IQR Interquartile range
